Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Patent application title: PTEROSTILBENE AND CURCUMIN COMBINATION FOR TREATMENT OF OXIDATIVE STRESS AND INFLAMMATION
Assignees: ChromaDex Inc.
Read more: http://www.faqs.org/patents/app/20130296440#ixzz2k5FcI6jZ
Any moment now… Is curcumin momentum building towards a tipping point?
It has been described as ‘one of the biggest-growing products in the botanical market right now’ and ‘the next omega-3’, so is the momentum building towards a tipping point for curcumin?
http://www.nutraingredients-usa.com/Suppliers2/Any-moment-now-Is-curcumin-momentum-building-towards-a-tipping-point
otc is down.....
Looks like otc is down.....
OPKO Commences Pivotal Clinical Validation Study for 4Kscore™ as a Predictor of Prostate Cancer Prior to Biopsy
http://investor.opko.com/releases.cfm
just traders that bought in lower taking their profit...
I am an investor of opk....not a trader..so 1 week means nothing to me...I bought in the 4's and this price here is nothing to what I will make off of Frost's company in the future...I'm patient...
A much needed pullback....
Your Future Energy Drink Will Blow Your Hair Back With Stronger Caffeine That Lasts Longer..........
http://www.fastcoexist.com/3020191/futurist-forum/your-future-energy-drink-will-blow-your-hair-back-with-stronger-caffeine-that...
The rise of questionably safe ultra-caffeinated food products has triggered the FDA in recent months to examine whether it really makes sense to stick the stimulant in "non-traditional" products like energy drinks and gum.
ChromaDex, a company that makes and licenses intellectual property for nature-identical ingredients (that is, natural ingredients which are produced synthetically), is on a mission to make sure that caffeine addicts still get their fix, even if the FDA decides to launch a dramatic crackdown.
It delivers 30% more caffeine into the blood, and is absorbed by the body at a 30% slower rate.
The company recently announced human clinical trial results for Purenergy, a caffeine-related ingredient that the company says delivers 30% more caffeine into the blood than traditional caffeine, is absorbed by the body at a 30% slower rate than regular caffeine (so it lasts longer), and cuts the half-life of caffeine by one quarter. Purenergy could, in other words, offer the same energy boost as traditional caffeine in significantly lower quantities, circumventing any future FDA caffeine limits for products.
For years, ChromaDex has been licensing IP for ingredients instead of developing them in-house. For instance, pTeroPure, a nature-identical version of trans-Pterostilbene--an ingredient found in blueberries that lowers blood pressure and has a calming effect--is found in up to 50 commercial products, including many dietary supplements.
But with Purenergy, Chromadex is getting into the market itself. The product is a caffeine and pTeroPure hybrid that--theoretically--nullifies caffeine's negative effects with the positive ones from pTeroPure. "pTeroPure is good for reducing blood pressure, and the negative side effects of caffeine are anxiety and hypertension related, so it cancels it out," claims ChromaDex CEO Frank Jaksch, Jr.
Supposedly co-crystallizing the two ingredients--bringing them together into one hydrogen-bonded whole--intensifies caffeine absorption and makes it last longer in the body. "The benefits of Purenergy come from the crystallization process," says Jaksch.
This kind of prolonged fix doesn't come cheap. Jaksch says that Purenergy will be a "premium-priced ingredient" compared to traditional caffeine. But if the FDA ever cracks down on caffeine, there may not be many options for energy product companies, except to find ways to do more with less caffeine. Non-caffeine alternatives that deliver a similar energy boost tend to be in a class of compounds called alkaloids (caffeine is an alkaloid; so is nicotine). But, says Jaksch, "The FDA stance is very clear: There's no chance in hell they're going to let a new alkaloid that's a stimulant onto the market unless someone brought in a huge battery of data."
ChromaDex is in the process of marketing Purenergy to companies now. Jaksch couldn't reveal any potential partnerships, but don't be surprised if Purenergy shows up in your Red Bull or Monster energy drink in the near future.
only if you are a trader...not for longs like me....I have owned this stock for a while now with no intention of selling....and any news could send it either way in the short term...
longs are looking at the ytd chart ...not the weekly...but I agree with you because we have been waiting on this....
oh I know...I have held cdxc for quite a while....bought around .65...I am not going anywhere....I am just talking strictly about the chart...setting up nicely....
we need to break .96 resistance and then the big W is complete...support at .87...I wish we would do it already
if you are brave enough
we have a nice big W formed...I would be looking for a breakout soon...chart looks good...
I think you are wrong...unless the market falls big...keep in mind markets love govt. shutdowns...and the charts show support at this level...just like we sat at .65 for a long time....
don't worry...cdxc is looking stronger than it ever has...keep in mind it is a stock under $1....it gets played with by the traders...
Chromadex....Clinical Study Demonstrates ChromaDex's Caffeine Alternative, PURENERGY™, Delivers 30% More Caffeine, Stays in the Blood Stream Longer and is Absorbed More Slowly than Ordinary Caffeine
http://www.heraldonline.com/2013/09/25/5243196/clinical-study-demonstrates-chromadexs.html
don't worry about it..one small sell of 100 shs brought it down...means nothing....
any thoughts to why the hell cdxc is not trading at all....
Natural Products Ingredient Innovator Generating Interest Among Investors Institutions and Industry...........May 15, 2013 (ACCESSWIRE-TNW via COMTEX) -- ChromaDex (CDXC) emerging as significant player...............http://www.marketwatch.com/story/natural-products-ingredient-innovator-generating-interest-among-investors-institutions-and-industry-2013-05-15?pagenumber=1
In Opko Health's most recent presentation at the Annual JP Morgan Biotech conference they displayed some information that many investors appeared to not have been aware of thus far. The presentation discussed that their new diagnostic technology is in fact not only capable of diagnosing through blood samples, but can also use samples of urine, saliva, sweat, tears, semen, amniotic fluid, spinal fluid and serum. I considered this valuable info since OPK also discussed its diagnostic system testing various other areas such as STDs, fertility, cardiology and more. Further interesting news that OPK disclosed is that they are projecting to launch their 4Kscore™ LDT for prostate cancer by Q2 2013 in the US.
Dr. Oz and Bryce Wylde Recommend Two Supplements Sold by ChromaDex..........http://www.trefis.com/stock/cdxc/articles/164911/dr-oz-and-bryce-wylde-recommend-two-supplements-sold-by-chromadex/2013-01-23
Why Dr. Oz’s Endorsement Of ChromaDex’s Product Is Huge...http://www.trefis.com/stock/cdxc/articles/164105/why-dr-ozs-endorsement-of-chromadexs-product-is-huge/2013-01-18
Dr. Oz Endorses Two Compounds Found In ChromaDex Product Line.....http://investmentunderground.com/6410/featured/dr-oz-endorses-two-compounds-found-in-chromadex-product-line/
Blueberries for Blood Pressure? A Berry Interesting Concept.............Dr. Oz Blog.......http://blog.doctoroz.com/in-the-news/blueberries-for-blood-pressure-a-berry-interesting-concept
Dr. OZ video om pterostibene and C3G....
.http://www.doctoroz.com/videos/life-extending-power-antioxidants-pt-2
Sprouts Farmers Market...Frank Jaksch, president, CEO and cofounder of ChromaDex, and Michele Lobo, vice president of nutrition body care for Presence Marketing/Dynamic Presence, were appointed as directors of the Natural Products Association Board representing the supplier side. John Montague, founder and owner of Web Vitamins, was elected president of the NPA East region.
Could ‘controversial’ pharma court ruling provide ‘wiggle room’ for off-label dietary supplement marketing?/////////////http://www.nutraingredients-usa.com/Regulation/Could-controversial-pharma-court-ruling-provide-wiggle-room-for-off-label-dietary-supplement-marketing
TLSR: You follow OPKO Health Inc. (OPK:NYSE) and have an $8.50 price target on the company, which is almost a double from where it was recently trading. What is your value proposition for OPKO?
KD: There are several components to the OPKO story. I think of it as a smaller-cap, discovery-stage healthcare conglomerate. Most of the company's programs are in development stages. It has commercial revenues, primarily from pharmaceutical distribution businesses in Latin America. But most of the company's value is in its product pipeline, where it is developing both diagnostics and some biotech products.
"The sweet spot is still in companies that have a service model, that sell products where reimbursement is well understood and that can take advantage of growing test volumes."
I have focused much of my attention on the company's diagnostic programs, which could be novel and bring unique value. The company's lead commercial product on the diagnostic side is a test for prostate cancer, which is being positioned as a potential alternative to the prostate-specific antigen (PSA) test. We see a very high rate of false positives with PSA and treat a lot of patients when, in fact, they don't have disease. The value of OPKO's lead test is reduced overtreatment of patients.
TLSR: That is the kallikrein test, right?
KD: Yes. It's called 4Kscore. The next product out the door is likely a PSA test that would run alongside the 4Kscore test. Currently, all FDA-approved PSA tests must be sent to a central lab, like a LabCorp or a Quest, but OPKO's PSA test is unique because it would run on a point-of-care platform, meaning that it could be performed right in the office. The benefit is that doctors can give patients an answer 10–15 minutes after taking the blood draw, as opposed to having to call back later to provide an answer. The doctor also receives all revenues from the test instead of giving those revenues to Quest or LabCorp.
TLSR: You have written about OPKO's recent acquisition of Prost-Data Inc., a specialty pathology lab. How will that be accretive for the company?
Analyst Kevin DeGeeter: At the core of OPKO's strategy is the desire to have a fully integrated model. That means encompassing everything from discovery of new content to sales and marketing. OPKO did not have commercial infrastructure in place for urology testing. This acquisition brings in a well-respected commercial organization with a national distribution and sales channel that calls primarily on urologists, and primarily for oncology-oriented testing. What we have found, almost universally in the diagnostic world, is that it's easier to buy commercial infrastructure than to build it.
TLSR: This was a $40M acquisition. Part of Prost-Data's value proposition is that the company's pathologists, even the founder, will get on the phone and speak with a urologist who calls about a patient's biopsy. Is this a scalable model?
KD: It is. OPKO's focus will be less on adding to the customer base and more on building deeper relationships with more proprietary content. I expect the menu will continue to grow within the Prost-Data franchise.
NO NEED FOR ANY FINANCING IN NEAR FUTURE AT ALL...Frank says financial reports do not reflect what options company has to continue with future growth right now...so they have no plans to raise money and do not feel it is in best interest of stockholders....
Red Chip Conference..NR will be commercially released soon...not only have they had numerous interest from Universities and research but they have already been contacted from big corporations wanting to be involved with NR either in helping to launch it...license it..or what ever they can get...they want in.....as far as Blue Science they are in the process of getting a strategic partner soon to help with the line....sounds like real soon since he couldn't talk about where they are in the process....
this is their other subsidiary....
We’re taking aim at chronic disease and we won’t give up until we conquer.
Biospherics, a wholly owned subsidiary of Spherix Incorporated, is a leader in the application of chiral carbohydrate chemistry and research in the metabolic syndrome. The Company’s new lead candidate is SPX-106T, a therapeutic combination licensed from the college of pharmacy for reducing triglycerides, cholesterol and atherosclerosis. Biospherics also has phase 3 clinical trial results with D-tagatose, a naturally occurring, simple sugar being developed as an oral treatment for glycemic control in patients with Type 2 diabetes.
Spherix Incorporated is developing innovative biopharmaceutical products and providing technical and regulatory consulting services to food, consumer products and pharmaceutical companies. Through its two subsidiaries, Biospherics and Spherix Consulting, Spherix
strives to better the human condition.
The company also develops biopharmaceutical products through its Biospherics Inc. subsidiary.
ChromaDex bought all the stock of the consulting arm of the Bethesda, Md.-based research firm on undisclosed terms. Spherix said the sale was the initial step in a companywide restructuring program.
Spherix Consulting will operate as a subsidiary of ChromaDex, while maintaining its offices in the Washington, D.C. area. It will continue to be led by company founder and President Claire Kruger.
Spherix provides technical services and scientific support to manufacturers and retailers of dietary supplements, medical foods and other pharmaceutical products. The company also develops biopharmaceutical products through its Biospherics Inc. subsidiary.
zagdad...new news..I search every day for news....another good thing about this that I just thought of.....this acquisition also makes cdxc look better for a big pharma to acquire them in the future....especially one that has acquired a supplement company already....
this is a great acquisition for chromadex...with all the new regulation about to come down on the industry from the crazy obama administration....this was a smart move...the company is based in Washington D.C.
"By providing a more comprehensive suite of science-based and regulatory services, ChromaDex will to able to more efficiently advance products in the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical markets."
Spherix Consulting provides its clients in the food, supplement and pharmaceutical industries with effective solutions to manage potential health and regulatory risks. Its science-based solutions are for both new and existing products that may be subject to product liability and/or exposed to changing scientific standards or public perceptions; literature evaluations; and design and assessment of pre-clinical and clinical safety testing. Spherix Consulting specializes in regulatory submissions for food and dietary supplement ingredients (GRAS, NDIN, Food Additive Petitions, Novel Food Petitions). For its clients involved in drug development within the pharmaceutical industry, Spherix provides similar services as well as risk-based strategies, including intellectual property data and compliance gap identification, due diligence assessments and IND writing.
who do u think is going to be doing all the testing....chromadex
Michael Berry Applies His 10 Discovery Investing Factors to Biotech.....http://www.thelifesciencesreport.com/pub/na/14758
How ChromaDex Doubled Its Revenues.....http://community.nasdaq.com/News/2012-11/how-chromadex-doubled-its-revenues.aspx?storyid=191541#.UKz2s4dX3HQ